Skip to main content
. 2022 May 3;23(3):393–408. doi: 10.1007/s40257-022-00685-0
Download video file (100.1MB, mp4)

Video abstract: What is the long-term safety and efficacy profile of dupilumab in adults with moderate-to-severeatopic dermatitis for up to 4 years? (MP4 102515 KB)